



## A Novel Superoxide Dismutase Mimic, HSJ-0017, Reduces Radiation-Induced and Chemotherapy-Induced Damage

Bao-qiu LI<sup>1</sup>, Xin DONG<sup>2</sup>, Gui-qin YANG<sup>2</sup>, Na LI<sup>2</sup>, Ji-you GAO<sup>2</sup>,  
Shi-hong FANG<sup>2</sup>, Xian-chang GONG<sup>3</sup>, Shu-juan WANG<sup>4</sup> & Feng-shan WANG<sup>1\*</sup>

<sup>1</sup> School of Pharmaceutical Sciences, Shandong University,  
No.44, Wen Hua Xi Road, Jinan, Shandong 250012, China

<sup>2</sup> Shandong Hongli Laboratory Animal Experiment Co.,  
Ltd., A502, No.750, Shun Hua Road, Jinan, Shandong 250101, China

<sup>3</sup> Jinan Saiwen Pharmaceuticals, Inc., No.978, Tian Chen Road, Jinan, Shandong 250101, China

<sup>4</sup> Jilin Province A-Think Pharmaceutical Co.,Ltd., No.1, Yi Xin Road, Changchun, Jilin 130616, China

**SUMMARY.** Manganese(III)meso-tetra [3-(2-(2-methoxy)ethoxy)ethoxy]phenyl porphyrin chloride, designated HSJ-0017, is a novel superoxide dismutase mimic. The aim of the present study was to investigate the protective effect of HSJ-0017 on radiation-induced and chemotherapy-induced damage. B16/F1 murine melanoma cells were injected into mice. HSJ-0017 was given to mice prior to 10Gy whole-body irradiation. The peripheral blood white blood cells (WBC) and bone marrow cellularity of mice were analyzed. Tumor-bearing mice were given 1.0 mg/kg HSJ-0017 and were then given cyclophosphamide 24 h later. LD50 of cyclophosphamide was calculated. The peripheral blood WBC and bone marrow cellularity of mice were significantly recovered by HSJ-0017. The intravenous LD50 of cyclophosphamide was significantly increased. Slower tumor growth was observed in mice pre-treated with HSJ-0017. Our study has led to the view that HSJ-0017 can protect normal tissues against radiation and chemotherapy toxicity. HSJ-0017 may improve the tumor killing activity of radiation and cyclophosphamide.

**KEY WORDS:** Chemotherapy-induced damage, HSJ-0017, Manganese porphyrin, Mn<sup>III</sup>TE-3-PhPCI, Radiation-induced damage.

Author to whom correspondence should be addressed. *E-mail:* liqiu@163169.net.